Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403956 | 0.85 | IMPDH2 (0.57) | IMPDH2IMPDH1AHRMCL1DYRK1A | |
| SCHEMBL30309353 | 0.85 | IMPDH2 (0.57) | IMPDH2IMPDH1AHRMCL1DYRK1A | |
| SCHEMBL9746966 | 0.80 | PNMT (0.52) | IMPDH2IMPDH1PNMTMCL1DYRK1A | |
| SCHEMBL1015590 | 0.76 | MCL1 (0.58) | PNMTMCL1CA1CA2 | |
| SCHEMBL29489124 | 0.76 | CA1 (0.54) | IMPDH2IMPDH1PNMTMCL1DYRK1A | |
| SCHEMBL45954 | 0.76 | CA1 (0.54) | IMPDH2IMPDH1PNMTMCL1DYRK1A | |
| SCHEMBL7096071 | 0.74 | IMPDH2 (0.49) | IMPDH2IMPDH1AHRPRKCQPRKCD | |
| SCHEMBL4414444 | 0.72 | IMPDH2 (0.44) | IMPDH2IMPDH1AHRMCL1DYRK1A | |
| SCHEMBL8186005 | 0.71 | GRIN2D (0.43) | IMPDH2IMPDH1MCL1 | |
| SCHEMBL9747698 | 0.71 | MCL1 (0.43) | PNMTMCL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053108-B2 | Indoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-05-30 | — | — | US | disclosed |
| EP-1348704-B1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-6998403-B2 | Benzoindoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-02-14 | — | — | US | disclosed |
| EP-1516871-A1 | Benzoindoline derivatives with adrenergic activity | Les Laboratoires Servier (FR) | 2005-03-23 | — | — | EP | disclosed |
| US-20050059675-A1 | Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia | LES LABORATOIRES SERVIER (FR) | 2005-03-17 | — | — | US | disclosed |
| US-20040192736-A1 | New indoline compounds | LAVIELLE GILBERT (FR) | 2004-09-30 | — | — | US | disclosed |
| US-6759421-B2 | N-(3-PYRIDYL)-1,2-DIHYDRO-3H-BENZO(E)INDOLE-3-CARBOXAMIDE DERIVATIVES USEFUL AS A 5-HT2C ANTAGONIST | LES LABORATOIRES SERVIER (FR) | 2004-07-06 | — | — | US | disclosed |
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1348704-A1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | TPH1, IDO1, HTR3A | IMPDH2 369/4885IMPDH1 208/4885PNMT 240/4885 |
| US-20040192736-A1 | New indoline compounds | TPH1, HTR3A, HTR1D | IMPDH2 425/4885IMPDH1 232/4885PNMT 709/4885 |
| US-20050059675-A1 | Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia | HTR2C, HTR2A, ADRA2C | IMPDH2 1204/4885IMPDH1 1945/4885PNMT 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.